Title: Maternal dexamethasone before preterm births: implications for lower middle-income countries
Abstract: We congratulate Caroline A Crowther and colleagues on their much needed multicentre trial 1 Crowther CA Ashwood P Andersen CC et al. Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial. Lancet Child Adolesc Health. 2019; 3: 769-780 Summary Full Text Full Text PDF Scopus (38) Google Scholar of antenatal corticosteroids for preterm birth which has implications in lower middle-income countries. Betamethasone and dexamethasone were equally efficacious in preventing complications of prematurity, with dexamethasone being superior to betamethasone in terms of their safety and side-effect profiles. Here, we discuss some potential issues. Maternal dexamethasone before preterm births: implications for lower middle-income countries – Authors' replyWe thank Tanushree Sahoo and Abhishek Somasekhara Aradhya for their letter about our ASTEROID trial.1 Full-Text PDF Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trialThe incidence of survival without neurosensory disability at age 2 years did not differ between dexamethasone and betamethasone treatment. Our findings indicate that either antenatal corticosteroid can be given to women before preterm birth to improve infant and child health. Full-Text PDF
Publication Year: 2019
Publication Date: 2019-12-12
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot